Trombosis Vena Dalam Pasca Total Knee Arthroplasty dengan Profilaksis Rivaroksaban Oral

Indah Permata Hasnul, Dadang Rukanta, R. Anita Indriyanti

Abstract


Osteoartritis adalah penyakit degeneratif kronis, ditandai dengan kerusakan tulang rawan sendi. Penatalaksanaan osteoartritis memiliki dua modalitas terapi, yaitu terapi non bedah dan bedah. Pada kasus ketidakstabilan sendi yang progresif diindikasikan untuk dilakukan tatalaksana bedah. Salah satu risiko terapi bedah adalah tromboemboli vena (TEV), merupakan penyebab morbiditas dan mortalitas utama pada pasien ortopedi yang dapat dicegah menggunakan tromboprofilaksis. Tujuan penelitian ini adalah untuk mengetahui angka kejadian TVD pada pasien OA lutut primer pasca TKA dengan profilaksis rivaroksaban oral. Telah dilakukan penelitian deskriptif cross sectional dengan pendekatan retrospektif yang dilakukan di RS Al-Islam Bandung periode 2015-2016. Data yang diambil merupakan data sekunder dari catatan medik pasien dengan mencatat gejala klinis yang muncul dan interpretasi dilakukan bersama dokter penanggung jawab pelayanan (DPJP) menggunakan skor Well. Hasil penelitian ditemukan 81,8% mengalami TVD unlikely dan 18,2% mengalami TVD likely. Pada penelitian ini, menunjukkan masih adanya kejadian TVD pada pasien OA lutut primer pasca TKA dengan profilaksis rivaroksaban oral. Terdapat penurunan risiko TVD (18,2%), pada pasien yang menjalani TKA dengan profilaksis rivaroksaban oral. Berdasarkan hipotesis potensial terapi dan aktivitas antitrombotik, rivaroksaban dipercaya sebagai antikoagulan yang dapat menurunkan risiko TVD.


Keywords


Antikoagulan Oral, Osteoartritis, Rivaroksaban, Total Knee Arthroplasty, Trombosis Vena Dalam

References


WHO. Osteoarthritis. World Health [Internet]. 2013;12(Osteoarthritis in Priority Medicines for Europe and the World 2013 Update):6–8. Tersedia pada: http://www.who.int/medicines/areas/priority_medicines/Ch6_12Osteo.pdf?ua=1

Soeroso J, Isbagio H, Kalim H, Broto R, Pramudiyo R. Osteoartritis. In: Buku Ajar Ilmu Penyakit Dalam. V. Jakarta: Internal Publishing; 2009. hal. 2538–48.

Plotnikoff R, Karunamuni N, Lytvyak E, Penfold C, Schopflocher D, Imayama I, et al. Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health [Internet]. 2015;15:1195. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4666016&tool=pmcentrez&rendertype=abstract

Louis S. Apley’s System of Orthopaedics and Fractures. 9th ed. Bristol: Hodder Arnold; 2010. 86-101, 324, 307-311 hal.

Rönn K, Reischl N, Gautier E, Jacobi M. Review Article Current Surgical Treatment of Knee Osteoarthritis. Arthritis. 2011;1–9.

Mulcahy H, Chew FS. Current concepts in knee replacement: Complications. Am J Roentgenol. 2014;202(1):76–86.

Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol [Internet]. 2013;6(6):677–95. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4124620&tool=pmcentrez&rendertype=abstract

Skinner N, Moran P. Case Management Adherence Guidelines - Deep Vein Thrombosis ( DVT ). 2008;1–60.

Modi S, Deisler R, Gozel K, Reicks P, Irwin E, Brunsvold M, et al. Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients. World J Emerg Surg [Internet]. 2016;11:24. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4898382

Thaler J, Pabinger I, Ay C. Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med. 2015;2(July):30.

Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J [Internet]. 2014;12(1):22. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4334601&tool=pmcentrez&rendertype=abstract

Ahrens I, Bode C. The benefits of (XARELTO ®) Across multiple Indications and the relevance to cardiologists. 2013;(October):114–9.

Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J [Internet]. 2013;11(1):10. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3726366&tool=pmcentrez&rendertype=abstract

Rahmadiyanti N, Tresnasari C, Alie IR. Derajat Keparahan Osteeoarthritis Lutut di RS Al-Islam Bandung Periode 1 Januari 2013 – 31 Desember 2015. Universitas Islam Bandung; 2016.

Sonjaya MR, Rukanta D, Widayanto. Karakteristik Pasien Osteoarthritis Lutut Primer di Poliklinik Ortopedi Rumah Sakit Al-Islam Bandung Tahun 2014. Universitas Islam Bandung; 2015.

Litwic A, Registrar S, Edwards M, Clinical M. Epidemiology and Burden of Osteoarthritis. 2013;44(0):185–99.

Yuqing Z, Jordan JM. Epidemiology of Ostearthritis. NIH Public Access. 2011;26(154):217–26.

Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Casp J Intern Med. 2011;2(2):205–12.

Casey E, Linn S, Murtaugh B, Casey E. Role of Sex Hormones in the Development of Osteoarthritis. PMRJ [Internet]. 2017;4(5):S169–73. Tersedia pada: http://dx.doi.org/10.1016/j.pmrj.2012.01.013

Lumpur K, Medicine G, Lumpur K, Lumpur K. Osteoarthritis and falls in the older person. 2013;(July):561–6.

Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.).

Scott D, Brenner B, Buller HR, Gallus AS, Anthonie W, Misselwitz F, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. 2010;2499–510.

Zhang Y, Jiang X, Sun Y. Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement. 2017;0(June):1–9.

Srivastava M, Singh M, Kapoor D. Pain management in orthopaedic surgeries : A major concern. 2012;(1).

Won YS, Kim M, Jun KW, Nam WS, Ahn S, Hwang J, et al. Incidence and Clinical Characteristics of Deep Vein Thrombosis (DVT) after Total Knee Arthroplasty (TKA) with DVT Chemoprophylaxis. 2014;(October):531–8.

Lee SY, Ro DH, Chung CY, Lee KM, Kwon S, Sung KH, et al. Incidence of Deep Vein Thrombosis after Major Lower Limb Orthopedic Surgery : Analysis of a Nationwide Claim Registry. 2015;56(1):139–45.

Khalafallah AA, Renu S, Sharp C, Hannan T. Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban. 2012;2–5.

Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolsim. Blood. 2014;124(7):1020–8.

Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. J Blood Med. 2011;2:59–69.

Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J [Internet]. 2013;11:25. Tersedia pada: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3896794&tool=pmcentrez&rendertype=abstract

Hillarp A, Baghaei F, Blixter IF. Effects of the oral , direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. 2011;(May 2010):133–9.




DOI: http://dx.doi.org/10.29313/kedokteran.v0i0.8315

Flag Counter    Â